Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4553 The efficacy of “rechallenge” peptide receptor radionuclide therapy (PRRT) may be inferior to that of the initial PRRT, while the safety profile remains comparable

Introduction: Data on efficacy and adverse events of re-challenge PRRT (re-PRRT) for patients with gastrointestinal neuroendocrine tumours (GI-NETs) are limited.

Conference:

Presenting Author: Heinrich M

Authors: Heinrich M, Lutz F, Alwers S, Däubler C, Buck A,

Keywords: gastrointestinal neuroendocrine tumour, somatostatin receptor directed PET, laboratory parameters, Progression-free survival,

#4338 Spot urine 5-HIAA creatinine ratio is comparable to 24hr urine collection for diagnosis of carcinoid syndrome

Introduction: Carcinoid syndrome (CS) constitutes up to 20% of functional neuroendocrine neoplasms and can lead to carcinoid crisis (CC), a potentially fatal complication during invasive procedures. Urine 5-hydroxyindoleacetic acid (5HIAA) is the preferred diagnostic biomarker for CS and prognostic marker for CC. 5HIAA is collected over 24-hours with strict dietary restriction for the 2 days prior as well as the day of the collection. False positive and negative results can occur due to under and over-collection. Patient inconvenience also contributes to the low request rate of this test.

Conference:

Presenting Author: Kong G

Authors: Chiang C, Gamage I, Del Olmo-Garcia M, Pasanen L, Wong H,

Keywords: carcinoid syndrome, carcinoid crisis, urine 5-HIAA, biomarker,

#3612 Cystatin C may serve as a suitable blood-based biomarker to monitor renal functional decline in patients scheduled for peptide receptor radionuclide therapy

Introduction: Peptide receptor radionuclide therapy (PRRT) for treating somatostatin receptor (SSTR)-positive tumors may be associated with nephrotoxicity.

Conference:

Presenting Author: Hasenauer N

Authors: Hasenauer N, Hartrampf P, Weich A, Higuchi T, Schirbel A,

Keywords: sstr, theragnostics, prrt, renal, nephrotoxicity,

#3281 Prediction of progression-free survival in patients with neuroendocrine tumors received 177Lu-Dotatate using circulating biomarkers

Introduction: Few circulating biomarkers are available for prediction of progression-free survival (PFS) in patients with advanced neuroendocrine tumors (NET) received 177Lu-Dotatate.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Chen L, Gnanasegaran G, Mandair D, Toumpanakis C, Caplin M,

Keywords: PRRT, survival, ESR, creatinine, CgA,

#2230 Does Somatostatin Receptor (SSR) Positive Tumor Volume Determined on Ga68 DOTANOC PET/CT in Patients with Paraganglioma (PGL)/Pheochromocytoma(PCC) Correlate with Biomarkers? An Explorative Study

Introduction: SSR PET/CT is used in workup of pts with PCC/ PGL. Correlation of tumour burden on PET & biomarkers 24 hr Urine Metanephrines (UMET), normetanephrine (UNMET), UMET:creatinine ratio (MET:Crea),UNMET:creatinine (UNMET:crea) & Chromogranin A (CGA) has not been done.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Steyn R

Authors: Steyn R, Prasad V,

Keywords: 68Ga DOTANOC PET CT, PGL, PCC,